NSI-189 PHOSPHATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H30N4O.H3O4P
Molecular Weight	464.495
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OP(O)(O)=O.CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2

InChI

InChIKey=LWHMGALTTIYPJU-UHFFFAOYSA-N

InChI=1S/C22H30N4O.H3O4P/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19;1-5(2,3)4/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24);(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	H3O4P
Molecular Weight	97.9952
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H30N4O
Molecular Weight	366.4998
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26643541 | http://www.neuralstem.com/docs/5Nov14CNSSummitFinal.pdf | http://www.neuralstem.com/pdf/NSI189-Radiation-induced-2016-Hawaii-Poster.pdf

NSI-189 is a novel oral drug which was developed by Neuralstem for the treatment of cognitive disorders. Now the drug is being tested in phase II of clinical trials in patients suffering from major depressive disorder. The mechanism of NSI-189 action is explained by its ability to stimulate the generation of new neurons in the hippocampus, however the exact target molecule is still unknown.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
neurogenesis 3 Target ID: GO:0022008 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26643541	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 173 Sources: https://clinicaltrials.gov/ct2/show/NCT02695472	Primary		Phase II 1132	Unknown Approved Use Unknown

AUC

Value	Dose	Analyte	Population
1144 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2791 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4384 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 3 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
17.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 1 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 2 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26643541	40 mg 3 times / day multiple, oral dose: 40 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NSI-189 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg 3 times / day multiple, oral Highest studied dose Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26643541 Page: p.1377	unhealthy, 40.5 n = 6 Health Status: unhealthy Condition: Major depressive disorder Age Group: 40.5 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/26643541 Page: p.1377	Sources: https://pubmed.ncbi.nlm.nih.gov/26643541 Page: p.1377

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY443040	https://www.001chemical.com/chem/search?q=DY443040
1PlusChem LLC	1P000X0J	https://www.1pchem.com/search?query=1P000X0J
A2B Chem	AA41987	http://a2bchem.com/prod/AA41987
AA Blocks	AA000WH3	http://aablocks.com/goods/Goods/detail?id=AA000WH3
AChemBlock	O33964	http://www.achemblock.com/catalogsearch/result/?q=O33964
AK Scientific	Y1438	https://aksci.com/item_detail.php?cat=Y1438
AOBIOUS INC	AOB87795	http://aobious.com/aobious/search?search_query=AOB87795
Aceschem	ACS019904	https://www.aceschem.com/catalog/search.do?q=ACS019904
Angene	AGN-PC-0WAJRA	http://www.angenechemical.com/productshow/AGN-PC-0WAJRA.html
ApexBio Technology	B1150	https://www.apexbt.com/catalogsearch/result/?q=B1150
AstaTech	11620	http://astatechinc.com/CPSResult.php?CRNO=11620
Capot Chemical	34023	https://www.capotchem.com/search.do?q=34023
ChemShuttle	111957	https://www.chemshuttle.com/catalogsearch/result/?q=111957
Combi-Blocks	QJ-8210	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-8210
Debye Scientific	DA-46482	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-46482
Excenen	EX-A277	http://www.excenen.com/searchresultlist.php?id=EX-A277
Fluorochem	466617	http://www.fluorochem.co.uk/Products/Product?code=466617
Hairui	HR33055	http://www.hairuichem.com/en/product/search.do?q=HR33055
KeyOrganics	AS-19608	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-19608
Lab Network	LN01318925	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01318925
Lab Seeker	SC-93118	http://www.labseeker.com/search.php?keywords=SC-93118&category=0
LabSeeker	SC-93118	http://www.labseeker.com/search.php?keywords=SC-93118&category=0
Matrix Scientific	147277	http://www.matrixscientific.com/147277.html
MolPort	MolPort-028-747-097	https://www.molport.com/shop/molecule-link/MolPort-028-747-097
Molcore	MC443040	http://www.molcore.com/CatMC443040.html
Molcore	MC446800	http://www.molcore.com/CatMC446800.html
Molnova	M11133	https://www.molnova.com/en/serch-list.html?keywords=M11133
MuseChem	I008377	https://www.musechem.com/product/I008377.html
MuseChem	I010177	https://www.musechem.com/product/I010177.html
PI Chemicals	PI-38517	http://www.pipharm.com/catalog_products/PI-38517.html
Ryan Scientific	SKLB_610	https://ryansci.com/products?q=SKLB_610&list_q=&search_type=exact
Selleck Chemicals	S5620	http://www.selleckchem.com/search.html?searchDTO.searchParam=S5620
ShangHai Biochempartner	BCP08748	http://www.biochempartner.com/search_BCP08748
TargetMol	T1833	https://www.targetmol.com/search?keyword=T1833
Toronto Research Chemicals	D826523	https://www.trc-canada.com/product-detail/?CatNum=D826523
Toronto Research Chemicals	N900600	https://www.trc-canada.com/product-detail/?CatNum=N900600
Wonderchem	WD09HXL	http://www.wonder-chem.com/search.html?text=WD09HXL
eMolecules	194971111	https://orderbb.emolecules.com/search/#?query=194971111
eMolecules	49837410	https://orderbb.emolecules.com/search/#?query=49837410
mcule	MCULE-1544231957	https://mcule.com/MCULE-1544231957/

PubMed

Title	Date	PubMed
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.	2016 Oct	27528461

Patents

Sample Use Guides

In Vivo Use Guide

40 mg of NSI-189 are administered orally once or twice daily for 28 days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:16:25 GMT 2023` Edited by `admin` on `Sat Dec 16 09:16:25 GMT 2023`
Record UNII	HX0VO60T62
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSI-189 PHOSPHATE

Common Name

English

METHANONE, (2-((3-METHYLBUTYL)AMINO)-3-PYRIDINYL)(4-(PHENYLMETHYL)-1-PIPERAZINYL)-, PHOSPHATE (1:1)

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

647018

Created by admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023

Code System Code Type Description

FDA UNII

HX0VO60T62

Created by admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023

PRIMARY

PUBCHEM

50922680

Created by admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023

PRIMARY

CAS

1270138-41-4

Created by admin on Sat Dec 16 09:16:25 GMT 2023 , Edited by admin on Sat Dec 16 09:16:25 GMT 2023

PRIMARY

Related Record Type Details


					YVE9U408ZL

NSI-189

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					YVE9U408ZL

NSI-189

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26643541 | http://www.neuralstem.com/docs/5Nov14CNSSummitFinal.pdf | http://www.neuralstem.com/pdf/NSI189-Radiation-induced-2016-Hawaii-Poster.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

AUC

T1/2

Doses

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26643541 | http://www.neuralstem.com/docs/5Nov14CNSSummitFinal.pdf | http://www.neuralstem.com/pdf/NSI189-Radiation-induced-2016-Hawaii-Poster.pdf

T_1/2